Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)

NCT07845500 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07845500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07845500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
February 16, 2028
Enrollment
660 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, overweight and/or obesity, treatment of obesity